Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Carvolix SA is a French clinical-stage medical technology company specializing in the development of AI-based mini-robots and biomimetic implants for cardiovascular treatments. Formed in early 2026 through the merger of Affluent Medical with Caranx Medical and Artedrone, it focuses on revolutionizing transcatheter aortic valve replacement (TAVR) and stroke care. Key products include the TAVIPILOT Software, an AI-driven guidance system with FDA clearance obtained in July 2025 for real-time intra-operative support, and the TAVIPILOT Robot, designed for precise, autonomous valve positioning to enhance procedural accuracy and accessibility. These innovations address unmet needs in structural heart diseases, targeting markets valued at over €23 billion by 2030, where currently only a fraction of patients receive treatment due to procedural complexity. Headquartered in Aix-en-Provence, France, and founded in 2011 with roots in Affluent Medical, Carvolix SA employs around 76 people and operates in the healthcare supplies sector, integrating micro-robotics, AI, and implant technologies to empower interventional cardiologists worldwide.
The business is unprofitable at the operating level (-355.44% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -€11M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€4M
Net Income (TTM)
-€15M
▲ +5.8% YoY
Op. Margin
-355.44%
ROIC
-24.35%
Cash Flow & Balance Sheet
FCF (TTM)
-€11M
▲ +6.3% YoY
Op. Cash Flow (TTM)
-€11M
▲ +6.2% YoY
Net Debt
€10M
Cash & Equiv.
€7M
Continue Research